

(19)



(11)

EP 1 870 417 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 51, 54

(51) Int Cl.:

C07K 1/107 ^(2006.01) **C07K 17/02** ^(2006.01)
C12P 19/34 ^(2006.01) **C12N 15/11** ^(2006.01)
C12N 15/10 ^(2006.01)

(48) Corrigendum issued on:

01.08.2012 Bulletin 2012/31

(45) Date of publication and mention
of the grant of the patent:

28.03.2012 Bulletin 2012/13

(21) Application number: **07005917.5**

(22) Date of filing: **19.07.2000**

(54) **Peptide acceptor ligation methods**

Peptidakzeptorbindungsverfahren

Procédé de ligature d'accepteur de peptide

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **27.07.1999 US 145834 P**

(43) Date of publication of application:

26.12.2007 Bulletin 2007/52

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

00947524.5 / 1 196 637

(73) Proprietor: **Bristol-Myers Squibb Company**
Princeton, NJ 08543-4000 (US)

(72) Inventors:

- **Kurz, Markus**
4054 Basel (CH)
- **Lohse, Peter**
Weston, MA 02493 (US)
- **Wagner, Richard**
Cambridge, MA 02138 (US)

(74) Representative: **Reitstötter - Kinzebach**

Patentanwälte
Sternwartstrasse 4
81679 München (DE)

(56) References cited:

WO-A-01/16352 WO-A-95/11922
WO-A-98/16636 WO-A-98/31700
DE-C- 19 646 372 US-A- 5 391 723

- **KURZ M ET AL: "Psoralen photo-crosslinked mRNA-puromycin conjugates: a novel template for the rapid and facile preparation of mRNA-protein fusions." NUCLEIC ACIDS RESEARCH 15 SEP 2000, vol. 28, no. 18, 15 September 2000 (2000-09-15), page E83, XP002466472 ISSN: 1362-4962**
- **PIELES U ET AL: "PSORALEN COVALENTLY LINKED TO OLIGODEOXYRIBONUCLEOTIDES : SYNTHESISSEQUENCE SPECIFIC RECOGNITION OF DNA AND PHOTO-CROSS-LINKING TO PYRAMIDINE RESIDUES OF DNA" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 1, 1989, pages 285-299, XP000651687 ISSN: 0305-1048**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 870 417 B9

- **PIELES U ET AL:** "PREPARATION OF A NOVEL PSORALEN CONTAINING DEOXYADENOSINE BUILDING BLOCK FOR THE FACILE SOLID PHASE SYNTHESIS OF PSORALEN-MODIFIED OLIGONUCLEOTIDES FOR A SEQUENCE SPECIFIC CROSSLINK TO A GIVEN TARGET SEQUENCE" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 22, 25 November 1989 (1989-11-25), pages 8967-8978, XP002052847 ISSN: 0305-1048
- **TUNITSKAYA V L ET AL:** "Mapping of T7 RNA polymerase active site with novel reagents - oligonucleotides with reactive dialdehyde groups" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 442, no. 1, 8 January 1999 (1999-01-08), pages 20-24, XP004258995 ISSN: 0014-5793
- **ERMOLINSKI B S ET AL:** "[Periodate oxidation in chemistry of nucleic acid. Dialdehyde derivatives of nucleosides, nucleotides, and oligonucleotides]" BIOORGANICHESKAIA KHIMIJA JUL 2000, vol. 26, no. 7, July 2000 (2000-07), pages 483-504, XP002466473 ISSN: 0132-3423
- **ROBERTS R W ET AL:** "RNA-PEPTIDE FUSIONS FOR THE IN VITRO SELECTION OF PEPTIDES AND PROTEINS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, November 1997 (1997-11), pages 12297-12302, XP000904377 ISSN: 0027-8424
- **ROBERTS R W:** "Totally in vitro protein selection using mRNA-protein fusions and ribosome display" CURRENT OPINION IN CHEMICAL BIOLOGY, CURRENT BIOLOGY LTD, LONDON, GB, vol. 3, June 1999 (1999-06), pages 268-273, XP002180767 ISSN: 1367-5931
- **LIU R ET AL:** "19 OPTIMIZED SYNTHESIS OF RNA-PROTEIN FUSIONS FOR IN VITRO PROTEIN SELECTION" METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 318, 2000, pages 268-293, XP002909305 ISSN: 0076-6879
- **MISIURA K ET AL:** "BIOTINYL AND PHOSPHOTYROSINYL PHOSPHORAMIDITE DERIVATIVES USEFUL IN THE INCORPORATION OF MULTIPLE REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 18, no. 15, 11 August 1990 (1990-08-11), pages 4345-4354, XP000601413 ISSN: 0305-1048
- **NEMOTO N ET AL:** "In vitro virus: Bonding of mRNA bearing puromycin at the 3 [prime]-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 414, no. 2, 8 September 1997 (1997-09-08), pages 405-408, XP004366358 ISSN: 0014-5793
- **BUCHARDT O ET AL:** "PEPTIDE NUCLEIC ACIDS AND THEIR POTENTIAL APPLICATIONS IN BIOTECHNOLOGY" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 11, 1 September 1993 (1993-09-01), pages 384-386, XP000606271 ISSN: 0167-7799

Description

Background of the Invention

[0001] In general, the present invention relates to ligation methods, in particular, for joining peptide acceptors to nucleic acids.

[0002] Methods currently exist for the preparation of RNA-protein fusions. An RNA-protein fusion is created by attaching a peptide acceptor to the 3' end of an RNA molecule, followed by *in vitro* or *in situ* translation of the RNA. The product is a peptide attached to the 3' end of the RNA encoding it. The generation of these RNA-protein fusions facilitates the isolation of proteins with desired properties from large pools of partially or completely random amino acid sequences, and solves the problem of recovering and amplifying protein sequence information by covalently attaching the RNA coding sequence to its corresponding protein molecule.

[0003] The use of T4 DNA ligase to attach the peptide acceptor puromycin to RNA by way of a DNA "splint" is described in WO98/31700. WO98/31700 also describes the preparation of minimal translation templates containing 3' puromycin by attachment of individual nucleotides to immobilized puromycin using standard phosphoramidate based oligonucleotide synthesis.

[0004] Roberts and Szostak (PNAS 94:12297-12302, 1997) report on the preparation of synthetic RNAs with 3' puromycin by using immobilized puromycin as a support for standard synthesis of an oligonucleotide linker, and ligating the resulting puromycin linker molecule to a polypeptide-encoding RNA in T4 DNA ligase buffer.

[0005] A method for the preparation of RNA-DNA chimeric ligation products comprising 3' puromycin by using T4 RNA ligase is described in WO98/155636.

[0006] Tuniskaya et al. (FEBS Letters 442: 20-24, 1999) report on protein-nucleic acid interaction studies using 2'-O- β -riboRNAosyl-cytidine containing oligonucleotides that were IO_4^- oxidized in order to yield the corresponding dialdehydes that allow covalent binding to the protein investigated.

[0007] Pieleas et al. (Nucleic Acids Research 17(22), 8967-77, 1989) describe covalent bond formation between an oligonucleotide carrying psoralen and the complementary matrix strand by photoreaction.

[0008] Non-nucleosidic phosphoramidite linker units for direct incorporation of reporter groups during oligonucleotide synthesis have been described by Misiura et al. (Nucleic Acids Res. 18(15): 4345-54, 1990).

Summary of the Invention

[0009] The present invention features methods for the attachment of a peptide acceptor to an RNA molecule as well as the RNA-peptide acceptor products. These methods facilitate the production of RNA-protein fusions which can be used, for example, for the isolation of proteins or nucleic acids with desired properties from large pools of

partially or completely random amino acid or nucleic acid sequences. This inventive method may be carried out by a variety of strategies for affixing a peptide acceptor to a nucleic acid molecule. These various approaches differ from one another in the types of bonds formed by the attachment of the peptide to the nucleic acid, and in the reagents used to achieve the attachment.

[0010] Described herein is a method for affixing a peptide acceptor to an RNA molecule involving providing an RNA molecule having a 3' sequence which forms a hairpin structure, providing a peptide acceptor covalently bonded to a nucleic acid linker molecule, and hybridizing the RNA molecule to the nucleic acid linker molecule under conditions which allow covalent bond formation to occur between the peptide acceptor and the RNA molecule.

[0011] Further described herein is a method for affixing a peptide acceptor to an RNA molecule involving providing a peptide acceptor having a linker with a 5' sequence that forms a hairpin, hybridizing the peptide acceptor to the RNA molecule, and covalently bonding the peptide acceptor to the RNA.

[0012] In a first aspect, the invention features a method of affixing a peptide acceptor to an RNA molecule by chemically ligating the RNA molecule to the peptide acceptor.

[0013] In one embodiment of this aspect, the peptide acceptor is joined to a psoralen moiety and crosslinked to the RNA molecule via the psoralen moiety. The psoralen moiety may be attached to either the 5' or 3' end of a linker molecule which is itself attached to the peptide acceptor, or the psoralen moiety may be located at an internal position of the linker molecule. According to this technique, the peptide acceptor is crosslinked to the RNA molecule using UV irradiation. In further embodiments of this particular aspect, the psoralen is attached to the peptide acceptor through a C6 alkyl chain and/or the RNA molecule contains a stop codon positioned proximal to its 3' end. Preferably, the linker is between 25 and 40 nucleotide units in length. In addition, prior to crosslinking the peptide acceptor to the RNA molecule, the RNA may be hybridized to a linker that further includes a photocleavable moiety. The hybridized RNA may then be immobilized to a solid support through the photocleavable moiety. Preferably, the photocleavable moiety is biotin.

[0014] In another embodiment of the first aspect of the invention, the RNA molecule is functionalized and is attached to a peptide that has been suitably modified to permit chemical bond formation between the peptide acceptor and the RNA molecule. Preferably, the RNA molecule is functionalized through IO_4^- oxidation. The peptide acceptor may be functionalized by attaching a molecule to the peptide acceptor chosen from the group consisting of amines, hydrazines, (thio)hydrazides, and (thio)semicarbazones.

[0015] In yet another embodiment of the first aspect of the invention, the chemical ligation is carried out in the absence of an external template. Alternatively, the chem-

ical ligation reaction can be carried out in the presence of an external template. This second method involves aligning the RNA molecule and the linker portion of a peptide acceptor using a template, so that the 5' end of the template hybridizes to the linker portion of the peptide acceptor and the 3' end of the template hybridizes to the RNA molecule. The chemical ligation of an RNA molecule to a peptide acceptor can also be carried out in the absence of an external template by hybridizing the linker molecule itself, which is covalently bonded to the peptide acceptor, to the RNA molecule. This hybridization brings the peptide acceptor and RNA molecule into close proximity for ligation. Preferably, the functional group is at the 5' end of the linker region of the peptide acceptor, or is flanked by a hybridization domain on one side and the peptide acceptor on the other side.

[0016] In a further embodiment of the first aspect of the invention, the chemical ligation of the peptide acceptor to the RNA molecule involves attaching a functional group to the RNA molecule through reductive amination of the RNA, followed by modification of the peptide acceptor to react with the RNA molecule. The two molecules are then joined through formation of a covalent bond. Preferably, the functional group attached to the RNA molecule is a thiol, maleimide, or amine.

[0017] In yet other aspects, the invention features RNA molecules chemically ligated to peptide acceptors as well as the nucleic acid-protein fusions generated by transcription and translation (and, if desired, reverse transcription and/or amplification) of these RNA molecules. In one embodiment, the peptide acceptor is ligated at the 3' end of the RNA molecule.

[0018] Further described are methods for the selection of a desired protein or nucleic acid using the RNA-peptide acceptor molecules of the invention. The selection techniques utilize the present molecules for RNA-protein fusion formation, and subsequent selection of proteins or nucleic acids of interest. The selection methods may be carried out by any of the approaches described, for example, in Szostak et al., WO 98/31700, and Szostak et al., U.S.S.N. 09/247,190, hereby incorporated by reference.

[0019] In a final aspect, the invention features a method of generating an RNA-protein fusion. This method involves providing an RNA molecule hybridized to a linker, where the linker contains a photocleavable moiety, a psoralen moiety, and a peptide acceptor; immobilizing the RNA to a solid support under conditions in which non-immobilized RNA are substantially removed from the support; crosslinking the peptide acceptor to the RNA, through the psoralen moiety, whereby this crosslinking simultaneously releases the crosslinked RNA from the solid support; and translating the crosslinked RNA to form an RNA-fusion protein. In one embodiment, the photocleavable moiety is biotin.

[0020] In all of the above aspects of the invention, the RNA molecule may include a translation initiation sequence and a start codon operably linked to a candidate

protein coding sequence. In addition, one preferred peptide acceptor is puromycin, a nucleoside analog which adds to the C-terminus of a growing peptide chain and terminates translation. In one embodiment, the peptide acceptor includes puromycin attached to a linker, for example, a nucleotide linker. This linker facilitates the alignment of the peptide acceptor to the RNA molecule for attachment. In a further embodiment, the linker region of the peptide acceptor includes non-nucleotide moieties, for example, PEG. Other possible choices for acceptors include tRNA-like structures at the 3' end of the RNA, as well as other compounds that act in a manner similar to puromycin. Such compounds include, without limitation, any compound which possesses an amino acid linked to an adenine or an adenine-like compound, such as the amino acid nucleotides, phenylalanyl-adenosine (A-Phe), tyrosyl adenosine (A-Tyr), and alanyl adenosine (A-Ala), as well as amide-linked structures, such as phenylalanyl 3' deoxy 3' amino adenosine, alanyl 3' deoxy 3' amino adenosine, and tyrosyl 3' deoxy 3' amino adenosine; in any of these compounds, any of the naturally-occurring L-amino acids or their analogs may be utilized. In addition, a combined tRNA-like 3' structure-puromycin conjugate may also be used in the invention.

[0021] In one preferred design of the invention, a DNA sequence is included between the end of the message and the peptide acceptor. This sequence is designed to cause the ribosome to pause at the end of the open reading frame, providing additional time for the peptide acceptor (for example, puromycin) to accept the nascent peptide chain before hydrolysis of the peptidyl-tRNA linkage. During *in vitro* translation the ribosome may also pause at the site of chemical ligation, especially at a psoralen crosslinking site or at a PNA clamp.

[0022] In another preferred design of the invention, predominantly non-nucleotide linker moieties may be used in place of the nucleotide linkers attached to the peptide acceptor. This design facilitates the ligation of a peptide acceptor to an RNA molecule. For example, the linker may contain triethylene glycol spacers. The linker may also contain 2'-OMe-RNA phosphoramidites. In some cases where hybridization is a prerequisite for chemical or enzymatic ligation, a sufficient portion of the linker next to the ligation site must be comprised of nucleic acids.

Furthermore, the RNA or linker of the invention may contain a sequence (e.g., a poly(A) sequence) for use in purification, for example, affinity purification of the RNA or an RNA-protein fusion molecule formed from such an RNA or linker.

[0023] In addition, in all of the above aspects of the invention the RNA molecule affixed to a peptide acceptor may be *in vitro* or *in situ* translated to produce an RNA-protein fusion molecule. The RNA-protein fusion molecule is then incubated in the presence of high salt and/or incubated at low temperature (e.g., overnight at -20°C) as described by Szostak et al. (09/247,190). The RNA-protein fusion molecule may be also purified, for exam-

ple, using standard poly(A) purification techniques.

[0024] As used herein, by a "protein" is meant any two or more naturally occurring or modified amino acids joined by one or more peptide bonds. "Protein" and "peptide" are used interchangeably.

[0025] By an "RNA" is meant a sequence of two or more covalently bonded, naturally occurring or modified ribonucleotides. One example of a modified RNA included within this term is phosphorothioate RNA.

[0026] By a "translation initiation sequence" is meant any sequence that is capable of providing a functional ribosome entry site. In bacterial systems, this region is sometimes referred to as a Shine-Dalgarno sequence.

[0027] By a "start codon" is meant three bases which signal the beginning of a protein coding sequence. By a "stop codon" is meant three bases which signal the termination of a protein coding sequence. Generally, start codons are AUG (or ATG) and stop codons are UAA (or TAA), UAG (or TAG), or UGA (or TGA); however, any other base triplets capable of being utilized as start or stop codons may be substituted.

[0028] By "covalently bonded" is meant joined together either directly through a covalent bond or indirectly through another covalently bonded sequence (for example, DNA corresponding to a pause site).

[0029] By "non-covalently bonded" is meant joined together by means other than a covalent bond.

[0030] By a "hairpin structure" is meant a double-stranded region formed by a single nucleic acid strand. Preferably, such hairpin structures are at least 8 base pairs in length, and more preferably, between 8 and 15 base pairs in length.

[0031] By "chemically ligating" is meant the joining together of two molecules without the use of an enzyme. Chemical ligation can result in non-covalent as well as covalent bonds.

[0032] By a "peptide acceptor" is meant any molecule capable of being added to the C-terminus of a growing protein chain by the catalytic activity of the ribosomal peptidyl transferase function. Typically, such molecules contain (i) a nucleotide or nucleotide-like moiety, for example adenosine or an adenosine analog (di-methylation at the N-6 amino position is acceptable), (ii) an amino acid or amino acid-like moiety, such as any of the 20 D- or L-amino acids or any amino acid analog thereof including O-methyl tyrosine or any of the analogs described by Ellman et al. (Meth. Enzymol. 202:301, 1991), and (iii) a linkage between the two (for example, an ester, amide, or ketone linkage at the 3' position or, less preferably, the 2' position). Preferably, this linkage does not significantly perturb the pucker of the ring from the natural ribonucleotide conformation. Peptide acceptors may also possess a nucleophile, which may be, without limitation, an amino group, a hydroxyl group, or a sulfhydryl group. In addition, peptide acceptors may be composed of nucleotide mimetics, amino acid mimetics, or mimetics of the combined nucleotide-amino acid structure.

[0033] By a "linker" or "linker molecule" is meant a se-

quence that includes deoxyribonucleotides, ribonucleotides, or analogs thereof.

[0034] By "functionalize" is meant to modify in a manner that results in the attachment of a functional group or moiety. For example, an RNA molecule may be functionalized through IO_4^- oxidation or amination, or a peptide acceptor may be functionalized by attaching an amine, hydrazine, (thio)hydrazide, or (thio)semicarbazone group.

[0035] By an "external template," is meant a nucleic acid sequence which is added to a ligation reaction mixture, but which is not a part of the final product of the ligation reaction.

[0036] By "high salt" is meant having a concentration of a monovalent cation of at least 200 mM, and, preferably, at least 500 mM or even 1 M, and/or a concentration of a divalent or higher valence cation of at least 25 mM, preferably, at least 50 mM, and, most preferably, at least 100 mM.

[0037] By "affinity purification sequence" is meant a nucleotide sequence that is utilized in the purification of a nucleic acid or a nucleic acid-protein fusion molecule. For example, an affinity purification sequence may be a poly(A) sequence, such as A_{8-20} , which can be used for purification of nucleic acid or fusion molecules on oligodT cellulose. An affinity purification sequence may also be a polypeptide sequence that is used to purify a nucleic acid-protein fusion molecule. Other exemplary purification techniques are described by Szostak et al. U.S.S.N. 09/247,190.

[0038] The present invention provides a number of advantages. For example, the methods described herein facilitate the efficient ligation of peptide acceptors to RNA molecules, in some aspects, without the need for an external template to bring the RNA and peptide acceptor together. The invention also reduces the cost associated with the generation of an RNA-protein fusion.

[0039] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Detailed Description

[0040] The drawings will first briefly be described.

Brief Description of the Drawings

[0041]

FIGURE 1 is a schematic representation of exemplary steps involved in the ligation of a peptide acceptor linker to an RNA using T4 DNA ligase on a hairpin template. Either the RNA 3' sequence or the peptide acceptor linker is designed to form a hairpin structure, and the peptide acceptor linker hybridizes to the RNA, thus bringing the RNA and peptide acceptor into close proximity to each other.

FIGURE 2 is a schematic representation of exem-

plary steps involved in the ligation of a peptide acceptor linker to an RNA using terminal deoxynucleotidyl transferase.

FIGURE 3A is a schematic representation of exemplary steps involved in the 3' modification of an RNA through hydrazide and semicarbazone formation.

FIGURE 3B is a schematic representation of exemplary steps involved in the 3' modification of an RNA through reductive amination.

FIGURES 4A-4D are a series of diagrams showing exemplary strategies for the chemical ligation of a functionalized puromycin linker to a functionalized RNA. One strategy is template-independent (Figure 4A). Other strategies involve using external oligo templates to align the RNA and puromycin linker. In the strategies involving external oligo templates, the oligo template may hybridize to both the RNA and puromycin linker (Figure 4B), or be attached to the puromycin linker and hybridize to the RNA (Figure 4D). In addition, the functional group may be at the 5' end of (Figures 4B and 4C) or internal to (Figure 4D) the puromycin linker.

FIGURE 5 is a schematic representation of exemplary steps involved in the synthesis of a fully protected carbohydrazide phosphoramidite for use in a modified puromycin linker.

FIGURE 6 is a schematic representation of exemplary steps involved in the ligation of a peptide acceptor linker to an RNA by attaching a functional group to the 3' end of the RNA followed by chemical ligation. The functional group can then react with a suitably modified linker molecule to covalently bond the RNA and puromycin linker, through a thiol (A), maleimide (B), or amine group (C).

FIGURES 7A-7C are a series of schematic representations of exemplary steps involved in the ligation of a peptide acceptor to an RNA using photo-crosslinking. In this general method, a psoralen moiety attached to the puromycin linker crosslinks the puromycin linker to the RNA upon exposure to UV irradiation. The psoralen moiety can be at the 5' end of (Figure 7A), internal to (Figure 7B), or at the 3' end of (Figure 7C) the puromycin linker.

FIGURE 7D is a schematic representation of mRNAs used for photo-crosslink formation.

FIGURE 7E is a schematic representation of a duplex formed between the constant 3'-sequence of the mRNA (const. region of the mRNAs of Figure 7D)) and the photolinker showing the putative psoralen intercalation site. Also shown is the structure of psoralen, which was attached through a C6 alkyl chain to the 5'-phosphate of the linker. The variables x and y determine the number of dA-nucleotides and triethyleneglycol-units (TEG) in the linker, respectively. The autoradiograph on the left depicts the gel-electrophoretic analysis of the photo-crosslinking reaction between mRNA 1 and linker B.

FIGURE 7F is an image of a gel illustrating *in vitro*

translation and fusion formation. Protein synthesis from mRNA template 2 and template 3 is shown in lanes 1 and 3, respectively. Translation of mRNA templates photo-crosslinked to linker B produced mRNA-protein fusions (lanes 2 and 4). Template 3 carries a stop codon following the linker crosslink-site. Lane 5 shows the fusion product after purification on oligo-dT cellulose. A schematic representation of fusion formation using an mRNA molecule containing a stop codon is depicted above the image of the gel.

FIGURE 7G is an image of a gel illustrating the dependence of mRNA-protein fusion molecule yield on linker composition and on salt concentration.

FIGURE 7H is a schematic representation of the steps involved in the ligation of mRNA to photocleavable biotin-based hybridized linkers and their subsequent fusion formation.

FIGURE 8A is a schematic representation of the attachment of a puromycin linker to an RNA through (PNA)₂-RNA triplex formation. The puromycin linker is attached to two PNA molecules which bind to RNA forming a triple helix through strong non-covalent bonds.

FIGURE 8B is a schematic representation of steps involved in the synthesis of PNA-linker conjugates. The linker is attached to a solid support and modified to attach to the PNA. The PNA is then coupled to the desired linker, and the PNA linker molecule is deprotected and separated from the solid support.

[0042] Described herein are various methods of attaching a peptide acceptor to an RNA molecule. The RNA may be generated by any standard approach, including normal cellular synthesis, recombinant techniques, and chemical synthesis, and includes, without limitation, cellular RNA, mRNA libraries, and random synthetic RNA libraries. The peptide acceptor (for example, puromycin) is typically bonded to a DNA or RNA linker. Such peptide acceptor molecules may be generated by any standard technique, for example, the technique described in Roberts and Szostak (Proc. Natl. Acad. Sci. USA 94:12297, 1997), Szostak et al. (WO 98/31700), and Szostak et al., U.S.S.N. 09/247,190. Techniques for carrying out each method of the invention are now described in detail, using particular examples and reference examples. These examples are provided for the purpose of illustrating the invention, and should not be construed as limiting.

Reference example 1: Enzymatic Ligation Methods Involving T4 DNA Ligase on a Hairpin Template

[0043] In one particular approach T4 DNA ligase is used to attach a peptide acceptor to an RNA molecule using a hairpin-containing template, for example, as shown in Figure 1. The ligation reaction is carried out in a self-templating manner and does not utilize a splint oligo. Either the RNA 3' sequence or the 5' end of the

linker region of the peptide acceptor is designed to form a hairpin structure. Close positioning of the 5' end of the linker region of the peptide acceptor and the 3' end of the RNA in the context of a hairpin structure facilitates enzymatic ligation with T4 DNA ligase, as described, for example, in Sambrook, Fritsch, & Maniatis. *Molecular Cloning*, Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press, 1989. The ratio of the reactants is approximately 1:1, although a slight excess (1:1.2) of either reactant is acceptable. Optimal ligation conditions may vary slightly from reaction to reaction and may be determined experimentally using techniques known to those skilled in the art.

Reference example 2: Enzymatic Ligation Methods Involving Terminal Transferase

[0044] Another enzymatic method for the attachment of a peptide acceptor to an RNA molecule involves the modification of the 3' end of the RNA followed by ligation using terminal deoxynucleotidyl transferase, for example, as shown in Figure 2. The TdT reaction is carried out as generally described in Sambrook, Fritsch, & Maniatis (*supra*). This enzyme extends the 3' end of nucleic acids with deoxy- (or dideoxy-) nucleotide triphosphates. These (d/dd)NTPs may be chemically modified on their base moieties to carry the desired linker structures (as described, for example, in Meyer, *Methods in Molecular Biology*, Agrawal, ed., vol 26, Totowa: Humana Press, 1994, pages 73-91; Kumar et al., *Anal. Biochem.* 169: 376, 1988; Riley et al., *DNA* 5:333, 1986; and Schmitz et al., *Anal. Biochem.* 192:222, 1991). As shown in Figure 2, the linker molecule must initiate with a (d/dd) NTP. The remainder of the linker composition, however, may vary. A special feature of this terminal transferase ligation method is that the DNA linker region of the peptide acceptor can be as short as one (d/dd)NTP unit.

Example 1: Chemical Ligation Methods Involving Functionalization of the 3' End of an RNA Through IO_4^- Oxidation Followed by Chemical Ligation

[0045] According to the methods of the invention, a peptide acceptor can also be attached to an RNA molecule by functionalization of the 3' end of the RNA via IO_4^- oxidation, followed by chemical ligation of the peptide acceptor to the RNA, as shown in Figure 3A. The IO_4^- oxidation is carried out as described below and according to the methods of Agrawal (*Methods in Molecular Biology*, Agrawal, ed., vol 26, Totowa: Humana Press, 1994, pages 93-120), Proudnikov and Mirzabekov, *Nucleic Acids Res.* 24:4535, 1996; Gosh et al., *Anal. Biochem.* 178: 43, 1989; Bauman et al., *J. Histochem. Bauman et al., J. Histochem. Cytochem.* 29:227, 1981; and Wu et al., *Nucleic Acids Res.* 24:3472, 1996). Since the IO_4^- oxidation step strictly requires a 1,2-diol for reaction, only the terminal nucleotide is modified, leaving internal residues of the RNA molecule unaffected. The resulting dialdehyde

can be subjected to a further reaction with various nucleophiles such as amines, hydrazines, carbo(thio)hydrazides, or (thio)semicarbazides, yielding Schiff base-like structures. These reactions are carried out as described, for example, in Agrawal (*supra*), Proudnikov and Mirzabekov (*supra*), Gosh et al. (*supra*), Bauman et al. (*supra*), and Wu et al. (*supra*). While the (thio)hydrazides and (thio)semicarbazones obtained after reaction with carbo(thio)hydrazides and (thio)semicarbazides, respectively, are fairly stable, the initial adducts containing amines or hydrazines usually require a subsequent reduction step, such as reductive amination, as shown in Figure 3B and as described in Agrawal (*supra*), Proudnikov and Mirzabekov (*supra*), Gosh et al. (*supra*), Bauman et al. (*supra*), and Wu et al. (*supra*), to render the newly formed bonds stable toward hydrolysis.

[0046] The above-described coupling reactions can be executed using a number of different strategies, as shown in Figures 4A-4D. For example, the ligation can be carried out in an external template-independent manner as shown in Figure 4A. This strategy requires a large excess of modified peptide acceptor (for example, 100 to 1000-fold excess) to achieve successful ligation to the RNA molecule. To increase the efficiency of the RNA ligation, external template oligos may be used for substrate alignment as shown in Figure 4B. Preferably, such oligos, which are complementary in sequence to the RNA and peptide acceptor linker sequences, are at least approximately ten nucleotides in length. Typically, this oligo will include at least approximately ten nucleotides which are complementary to the RNA molecule and approximately ten nucleotides which are complementary to the peptide acceptor linker. Alternatively, the reactive sites may be brought into close proximity by direct hybridization of linker and RNA domains as shown in Figures 4C-4D. Here, the extent of hybridizing sequence is at least ten to fifteen nucleotides.

[0047] A number of different constructs for the attachment of peptide acceptors to RNA via crosslink formation may be utilized. For example, one type of exemplary construct includes a peptide acceptor attached to a linker carrying a modification at its 5' end as shown in Figures 4A-4C. An alternative construct may comprise an internal functional group flanked by a hybridization domain on one side and a puromycin-linker portion on the other (Figure 4D).

[0048] The synthesis of these modified linkers involves standard automated DNA synthesis using commercially available phosphoramidites (Glen Research, Sterling, VA) for assembling the main body of nucleotides or spacer moieties. The 3' puromycin may be introduced through the use of puromycin-CPG (Glen Research, Sterling, VA) as a solid support for synthesis. The attachment of the reactive functional groups may be achieved using commercially available reagents such as amino terminus-modifiers (Glen Research, Sterling, VA) or uni-link amino modifiers (Clontech, Palo Alto, CA). Other functional groups may be incorporated utilizing appropriate phos-

phoramidites. One exemplary method to generate a carbohydrazide phosphoramidite is described in Figure 5. A carbohydrazide phosphoramidite was generated by combining a lactone with hydrazine and methanol and placing the reactants under reflux for 2 hours to produce a carbohydrazide moiety. The yield for this step of the synthesis was 97%. The resulting product was then reacted with the salt of a dimethoxytrityl group and pyridine/toluene at room temperature for 2.5 hours to yield a protected carbohydrazide moiety. The product yield for this step was 88%. This product was further reacted with a phosphoramidite moiety in the presence of tetrahydrofuran and diisopropylamine at room temperature for 30 minutes, which yielded (72%) a reaction product of a fully protected carbohydrazide phosphoramidite.

[0049] In addition, the reactivity of the peptide acceptor toward the IO₄⁻-oxidized RNA may be further enhanced through introduction of multiple copies of reactive groups.

[0050] One exemplary ligation reaction was carried out as follows. One nmole of RNA, consisting of a transcript encoding a flag epitope and a strep tag, of the sequence: 5' G GGA CAA UUA CUA UUU ACA AUU ACA AUG GAC UAC AAG GAC GAU GAC GAU AAG GGC GGC UGG UCC CAC CCC CAG UUC GAG AAG GCA UCC GCU (SEQ ID NO:1) was combined with 20 µl of 500 mM NaOAc (pH 5.2), 10 µl of 5 mM NaIO₄, and brought up to a final volume of 100 µl with water. The reaction mixture was incubated for 15 minutes at room temperature. Next, 10 µl of 10 mM Na₂SO₃ was added, and the reaction mixture was incubated again for 15 minutes at room temperature. Forty µl of 1 M phosphate buffer (pH 8.0), 1.5 nmole of the peptide acceptor linker Uni-A1/8, having the sequence: 5' X CGC GGA TGC AAA AAA AAA AAA AAA AAA CC Pu (SEQ ID NO: 2) (where X is a Uni-link amino modifier [Clontech], and Pu is Puromycin-CPG [Glen Research]), and 20 µl of NaCNBH₃ were added to the reaction mixture. The mixture was then incubated for 18 hours at room temperature, precipitated, purified on a 6% TBE-Urea gel, and crush-soaked overnight to obtain the RNA-protein fusion molecule. This reaction yielded 230 pmole of product.

Example 2: Chemical Ligation Methods Involving Attachment of Functional Groups to the 3' End of an RNA Molecule Followed by Chemical Ligation

[0051] A peptide acceptor can also be affixed to an RNA molecule by attaching a functional group to the 3' end of the RNA followed by chemical ligation, as shown in Figure 6. In a variation of the process described above, reductive amination and related reactions are used to attach functional groups to the 3' terminus of an RNA. These newly introduced groups then react further with suitably modified linkers on the peptide acceptor, leading to covalent bond formation between the RNA and peptide acceptor. Exemplary reactive groups include thiols (for disulfide formation or reactions with thiolphilic reagents such as pyridyl disulfides; Figure 6, Reaction A) or male-

imides (Figure 6, Reaction B).

[0052] Other possible reactive groups for the functionalization of the 3' end of an RNA followed by attachment of a peptide acceptor are amines. For example, N-hydroxysuccinimide-esters (NHS-esters) can be generated on 5' amino-modified linkers of the peptide acceptor by reaction with disuccinimidyl glutarate (DSG) or related reagents as described in Cox et al. (J. Immunol. 145: 1719, 1990) and <http://www.piercenet.com/Products/linksearch.cfm> (Pierce, Rockford, IL; Figure 6, Reaction C). This modified linker can then be reacted with the amino functional group of the modified RNA.

[0053] This type of ligation reaction may be carried out in either an external template-independent or -dependent manner as described above, using the same general approaches.

Example 3: Chemical Ligation Methods Involving Photochemical Methods

[0054] A peptide acceptor can also be attached to an RNA molecule using photochemical methods as shown in Figures 7A-7H. Peptide acceptor linker molecules that carry psoralen groups allow the introduction of crosslinks to complementary RNA strands upon irradiation with long wave UV-light. This technique may be carried out generally as described in Piles and Englisch, (Nucleic Acids Res. 17:285, 1989); and Godard et al. (Nucleic Acids Res. 22:4789, 1994). Attachment of the psoralen moiety to the 5' terminus of the linker region of the peptide acceptor can be accomplished using commercially available psoralen amidites, 2'-OMe-RNA phosphoramidites, psoralen C6 phosphoramidites, and triethylene glycol (TEG) phosphoramidites (Glen Research, Sterling, VA) on a standard DNA synthesizer.

[0055] In one exemplary approach, this method was carried out as follows. One nmole of RNA consisting of an RNA transcript encoding a flag epitope, a strep tag, and a photochemical target site of the sequence: 5' G GGA CAA UUA CUA UUU ACA AUU ACA AUG GAC UAC AAG GAC GAU GAC GAU AAG GGC GGC UGG UCC CAC CCC CAG UUC GAG AAG AAC GGC UAU A (SEQ ID NO:3), 1.2 nmole of Photolinker 30/10 consisting of the sequence: 5' Pso TAG CCG TTC T AAA AAA AAA AAA AAA AAA AAA AAA CC Pu (SEQ ID NO:4) (where Pso is a psoralen C2 amidite [Glen Research], and Pu is Puromycin-CPG [Glen Research]), synthesized according to standard manufacturer protocols, or 30/15 consisting of the sequence: 5' Pso TAG CCG TTC TTC TCG AAA AAA AAA AAA AAA AAA AAA AAA CC Pu (SEQ ID NO:5) (where Pso is a psoralen C2 amidite, and Pu is Puromycin-CPG), 10x buffer (250 mM Tris pH 7.0; 1 M NaCl), and water (bringing the final volume to 360 µl) were combined and heated to 80°C for 2 minutes. The reaction mixture was then slowly cooled to room temperature. The reaction mixture was next irradiated for 15 minutes at 0°C with λ greater than 310 nm using a 450 W immersion lamp (medium pressure;

ACE Glass, cat. no. 7825-34), equipped with a Pyrex absorption sleeve (ACE Glass, cat. no. 7835-44) in a Quartz immersion well (ACE Glass, cat. no. 7854-25), with the sample in a microcentrifuge tube strapped to the immersion well, and cooled in ice-water. The sample was then precipitated with 40 μ l of 3 M NaOAc and 1000 μ l of ethanol, and resuspended in 75 μ l of water. Next, 75 μ l of 2x loading buffer (Novex) was added to the sample, and the sample was purified on a precast 6% TBE-Urea gel (Novex). The product was recovered using a crush and soak method (0.3 M NaOAc, overnight at room temperature) followed by ethanol precipitation. This photocrosslinking method yielded 272 pmole of RNA-protein fusion product using Photolinker 10/30, and 227 pmole using Photolinker 15/30.

[0056] For this photocrosslinking method of chemical ligation, various parameters of the reaction were evaluated. First, the salt dependence of the photocrosslink formation was tested. A set of crosslinking experiments with buffers containing 100-1000 mM NaCl were performed. No difference in ligation efficiencies were observed between the various reactions. In addition, a change of the RNA target sequence to: 5'...GAC UAC AAG GAC GAG GCA UCC GCU CUU UCA CUA UA (SEQ ID NO:6) (with the underlined sequence being a target for the psoralen linker) gave significantly reduced product yields (15 to 20% reduced), indicating that the RNA target sequence was important. Next it was determined that the product yield could be increased by the repeated replacement of psoralen linkers that had been inactivated during the course of the reaction. This experiment was carried out as follows. The RNA, linker, and 10x buffer were combined and heated to 80°C for 2 minutes. The reaction mixture was then slowly cooled to room temperature and irradiated as described above. Then an additional 1 nmole of linker and 1 μ l of buffer were added. The linker annealed to the RNA and was then irradiated. This process was repeated, by adding 2 nmole of linker and 2 μ l of buffer and irradiating. This procedure allowed an increased product yield from 20% to greater than 40% for certain sequences.

[0057] The performance of the ligation products generated by photochemical crosslinking methods was also evaluated. In experiments with linkers of different lengths (psoralen plus 15 base pairs of target hybridization domain plus dA_nCCPu [where n=7, 12, 17, or 22]) the following observations were made. Long linkers gave the highest RNA-protein fusion yields under high salt conditions (500 mM KCl plus 50 mM MgCl₂). In buffers with reduced salt (250 mM KCl plus 10 mM MgCl₂, or 250 mM KCl), the short linkers produced higher yields than the longer ones, but the overall yields were generally lower. In general, yields seem to be comparable to those obtained with enzymatically ligated RNA templates.

[0058] In other exemplary methods, various mRNAs and puromycin linkers were synthesized such that the peptide acceptor was positioned at the 3' end of the linker. The linkers were annealed to the target mRNAs and eval-

uated for their efficiency in forming mRNA-protein fusions molecules through *in vitro* translation techniques. The effect of the linker length and composition on fusion molecule yield was also determined.

[0059] Figure 7D illustrates the design of the mRNAs used in the crosslinking reactions. Each of the RNA molecules contained a portion of the tobacco mosaic virus 5'-UTR (TMV) with good initiation codon context (Gallie et al., Nucleic Acids Res., 16:883-93, 1988; and Kozak, Microbiol. Rev., 47:1-45, 1983), and a translation initiation codon (AUG). All mRNAs also carried a 3'-terminal ten nucleotide linker hybridization sequence 5'-GCAUC-CGCUAAU coding for the amino acid sequence ASA, and ending with the dinucleotide sequence 5'-UA for psoralen photocrosslinking (const.), as described by Sinden and Hagerman (Biochemistry, 23:6299-6303, 1984) and Gamper et al., (Photochem. Photobiol., 40:29-34, 1984). In addition one mRNA (mRNA 1) contained a Flag epitope, DYKDDDDK (Hopp et al., Biotechnology, 6: 1205-1210, 1988) followed by a Strep-Tag II sequence, WSHYPQFEK (Schmidt et al., J. Mol. Biol., 255:753-66, 1996). Other mRNA molecules (mRNAs 2, 3, and 4) contained a 4-4-20 scFv, anti-fluorescein single chain antibody template, as described by Bedzyk et al. (J. Biol. Chem., 265:18615-20, 1990) and Mallender et al. (J. Biol. Chem., 271:5338-46, 1996). In addition, mRNAs 3 and 4 contained a downstream stop codon (UAA) to induce mRNA release from the ribosome after translation of residual un-crosslinked template (vide infra). A poly-A tail was also attached to mRNA 4 for purification by oligo-dT.

[0060] The mRNAs used in these studies (Figure 7D) were prepared by T7 RNA polymerase run off-transcription (Megashortscript Transcription Kit, Ambion, TX) of PCR DNA templates, according to the methods of Milligan et al. (Nucleic Acids Res., 15:8783-8798, 1987). After transcription, all RNAs were purified by electrophoresis on 6% TBE-urea polyacrylamide gels (Novex, CA). The product bands were visualized by UV-shadowing, excised, crushed, and soaked overnight in 0.3 M NaOAc. Following ethanol precipitation, the RNAs were resuspended and stored in H₂O. Radiolabeled RNA was synthesized according to the same procedure by including [α -³²P] UTP (Amersham, IL) in the transcription buffer.

[0061] The puromycin-linkers used in these studies (Figure 7E) were prepared using an Expedite Synthesizer Model 8909 (PerSeptive Biosystems, MA), using conventional solid-support phosphoramidite chemistry. Puromycin-CPG, DNA phosphoramidites, 2'-OMe-RNA phosphoramidites, psoralen C6 phosphoramidite, and triethylene glycol (TEG) phosphoramidites (spacer 9) were used according to the recommended protocols (Glen Research). A psoralen moiety was attached through a C6 alkyl chain to the 5'-phosphate of the linker. Flexible triethyleneglycol phosphate (TEG) spacers and polynucleotide sequences of various lengths were used to tether 5'-dCdC-puromycin to the 3'-end (see the table in Figure 7E). The linker hybridization sequence was prepared from 2'-OMe-RNA phosphoramidites to enhance

the pairing stability of the stem structure (Inoue et al., Nucleic Acids Res., 15:6131-6148, 1987; and Majlessi et al., Nucleic Acids Res., 26:2224-2229, 1998). Following deprotection in concentrated ammonium hydroxide for 8 hours at 55°C, the linkers were purified by reversed phase HPLC on a C18 Spheri-5 column (Perkin Elmer, CA) with 50 mM triethylammonium acetate in 5% v/v acetonitrile as buffer A, and 50 mM triethylammonium acetate in 70% v/v acetonitrile as buffer B and with a flow rate of 1.5 ml/min. A linear gradient of 15 - 60% buffer B over 45 minutes was used for elution. After drying, the linkers were resuspended and stored in H₂O.

[0062] The linkers (5 µM) were annealed to the target mRNAs (2.5 µM) in 25 mM Tris HCl buffer, pH 7, and 100 mM NaCl by heating to 85°C for 30 seconds, followed by cooling to 4°C over a period of 5 minutes. The reaction mixture was irradiated for 15 minutes at room temperature in borosilicate glass vials (Kimble/Kontes, NJ), using a handheld multiwavelength UV lamp model UVGL-25 (UVP, CA) set to a long wave (wavelength $\lambda > 300$ nm). The product mixture of the photocrosslinking reaction between radiolabeled mRNA 1 and linker B was analyzed on a denaturing 6% TBE-Urea gel (Novex) and visualized on a phosphorimaging system (Molecular Dynamics, CA) (Figure 7E). These photocrosslink product mixtures generally contained <20% unreacted and >80% photocrosslinked mRNA, and were used directly for *in vitro* translation and subsequent mRNA-protein fusion formation without further purification. For the longer mRNA substrates 2, 3, and 4 (> 800 nucleotides), the relative size difference between mRNA and crosslinked mRNA became too small to be separated on a gel. In these cases, the crude photo-crosslinking reaction mixtures were directly added to the lysate for fusion formation, without further purification.

[0063] Translation and fusion formation of the mRNA fusion molecules were first tested using mRNA 2 in the following experiments. *In vitro* translation reactions were performed using rabbit reticulocyte lysates (Ambion) for 30 minutes at 30°C. The reactions contained 100 pmole photo-crosslinked mRNA (see above), 10 mM creatine phosphate, 150 mM KOAc, 0.5 mM MgCl₂, 0.1 mM of each amino acid except methionine, 150 µCi of [³⁵S] methionine (Amersham), and 67% v/v of lysate in a total volume of 300 µl. mRNA-protein fusion formation was promoted by the addition of KCl and MgCl₂ to the final concentrations of 590 mM and 50 mM, respectively, in a 500 µl volume, according to the methods of Roberts & Szostak and Szostak et al. (*supra*). Incubation was continued for another 60 minutes at 20°C. Varying concentrations of KCl and MgCl₂ were also tested to explore salt dependence on fusion formation.

[0064] The *in vitro* translation products were isolated by diluting the lysate into 10 ml of binding buffer (100 mM Tris HCl, pH 8.0, 10 mM EDTA, 1 M NaCl, 0.25% v/v Triton X-100) and by adding to the mixture 10 mg of oligo-dT cellulose type 7 (Pharmacia, NJ). The samples were rotated for 60 minutes at 4°C. The solid support was then

washed with 5 ml of ice-cold binding buffer, followed by elution with 100 µl aliquots of deionized H₂O. The amount of mRNA-protein fusion isolated was determined by scintillation counting of the incorporated [³⁵S] methionine. The product was analyzed by electrophoresis on 4-12% NuPage gels using MES running buffer (Novex). The gels were dried after extensive washing to remove excess [³⁵S] methionine, and bands were visualized on a phosphorimager system (Molecular Dynamics).

[0065] Gel analysis showed two bands that corresponded to the peptidyl-tRNA and the free peptide (Figure 7F, lane 1). When translation was carried out with photo-crosslinked mRNA 2, a third and slower migrating band appeared, thus indicating successful mRNA-protein fusion formation (Figure 7F, lane 2). Increased yields of free protein and fusion (approximately 20% more) were obtained with mRNA 3, which was identical in coding sequence to mRNA 2, but carried a stop-codon downstream of the photo-crosslink site (Figure 7F, lanes 3 and 4). Relative band intensities indicated that 30% of the total amount of synthesized protein was converted into mRNA-protein fusion (Figure 7F, lane 4).

[0066] An mRNA-scFv fusion molecule, prepared from mRNA 4 of Figure 7E, was purified by binding of the A₁₈ linker regions to oligo-dT cellulose, followed by washing with binding buffer, according to the methods of Roberts & Szostak and Szostak et al. (*supra*) (Figure 7E, lane 5). The fusion product could be isolated with a 1.3% yield based on the amount of photo-crosslinked input mRNA. Physical properties (gel mobility, binding to oligo-dT cellulose, selective peptide binding to affinity reagents) of the fusions prepared from photo-crosslinked mRNA were found to be identical to those of the fusion product obtained from enzymatically ligated mRNA templates.

[0067] In order to confirm the composition of the peptide portion of the fusion molecules, fusions prepared from the mRNA template 1 crosslinked to linker B of Figure 7E, encoding the Flag and Strep-Tag II epitope, were tested for protein binding. A solution of 10 µl of ³⁵S-labeled mRNA-peptide fusion (prepared from mRNA 1 with linker B) was added to 20 µl of Anti-Flag M2 Affinity Gel (Sigma, MO) in 300 µl of buffer containing 50 mM Tris HCl, pH 7.4, 1% NP 40, 150 mM NaCl, 1 mM EDTA, 1 mM Na₃VO₄, and 1 mM NaF. A second precipitation experiment was carried out by adding the same fusion product to 20 µl of StrepTactin Sepharose (Genosys, TX) in 300 µl of buffer containing 100 mM Tris-HCl, pH 7.1, 1 mM EDTA, and 0.5 mg/ml yeast tRNA. Both precipitation mixtures were processed in parallel under identical conditions: The mixtures were rotated for 1 hour at 4°C and then transferred onto an Ultrafree-MC filter unit (0.45 µm; Millipore, MA). The buffer was removed by centrifugation, and the residue washed with 5 x 300 µl of ice-cold buffer. The residues were analyzed by scintillation counting, and fusion binding was determined to be 54% and 62% for the Anti-Flag M2 matrix and the StrepTactin matrix, respectively. A control reaction with protein-A agarose (Sigma) showed no detectable binding to the matrix.

[0068] To test the effect of linker length and composition on fusion formation in the presence of various salt concentrations, mRNA 3 was photo-crosslinked to linkers A-F of Figure 7E and each template was subsequently tested for fusion formation (Figure 7G). After incubation for 30 minutes at 30°C, the samples were divided into aliquots, to which varying amounts of KCl and MgCl₂ were added. The samples were incubated for another 60 minutes at 20°C; then, the fusion product was analyzed by gel-electrophoresis. The highest mRNA-protein fusion yields were obtained with the long linkers A and B (40 and 35 nucleotides, respectively) under high salt conditions. A lower salt concentration resulted in a significant drop in fusion formation with the linkers A and B. On the other hand, fusion yields for the shorter linkers C to F were less salt dependent. In addition, the fusion molecule yield generally increased with the number of flexible TEG spacers. Analysis of the crude mRNA-protein fusion molecule lysates revealed that up to 45% of the total protein was present as mRNA-protein fusion. Because linker F lacked the oligo-dA track needed for oligo-dT purification, mRNA 4 was prepared with an A₁₈ stretch at its 3'-end, which allowed fusion purification on oligo-dT cellulose.

[0069] In an alternative to the above techniques which involve attachment of psoralen to the linker 5' end, the psoralen moiety may also be incorporated at an internal position of the linker region of the peptide acceptor, as shown in Figure 7B, and as described in Pieles et al. (Nucleic Acids Res. 17:8967, 1989), or by incorporation of a branched phosphoramidite (Clontech, Palo Alto, CA) within the linker sequence, followed by addition of a psoralen phosphoramidite (Glen Research, Sterling, VA). For example, the psoralen moiety may be crosslinked to the RNA through a branched linker, as described in U.S.S.N. 09/453,190, incorporated herein by reference.

[0070] In one exemplary approach, a linker with the sequence 5' cgt agg cga gaa agt gat X AAA AAA AAA AAA AAA AAA AAA CC Pu (where Pu is Puromycin-CPG [Glen Research]; C and A are standard 3'-amidites [Glen Research]; a, t, c, and g are 5'-phosphoramidites [Glen Research]; and X is an asymmetric branching amidite [Clontech]) has been synthesized according to standard manufacturer protocols, followed by selective deprotection of the branching point X (according to the instructions of Clontech) and subsequent coupling of a psoralen C6 amidite (Glen Research). This linker was then photocrosslinked to an RNA with the target sequence 5'...GCA UCC GCU CUU UCA CUA UA using the photocrosslinking techniques described above. This RNA-linker construct was then successfully used for the synthesis of RNA-protein fusions.

[0071] In yet another alternative, a linker containing a psoralen attached to the 3' end of the target hybridization domain may also be constructed (Figure 7C). In this method, the 5' end of the psoralen-containing linker is extended by another linker, that after reversal of strand orientation, terminates with a 3' puromycin. A subsequent digestion of the RNA target domain with RNase H

is optional and will increase the flexibility of the linker construct. In addition, this approach allows the attachment of the linker at internal positions of much longer RNA molecules, and the untranslated region downstream from the linker site is then clipped off before translation and RNA-protein fusion formation.

[0072] In one exemplary approach to this method, a linker with the sequence 5' Pso atg cga gaa agt gat aaa aaa aaa CC Pu (where Pu is Puromycin-CPG [Glen Research]; C is a standard 3'-amidite [Glen Research]; a, t, c, and g are 5'-phosphoramidites [Glen Research]; and Pso is a psoralen C6 phosphoramidite [Gen Research]) was constructed according to standard manufacturer protocols. The linker was then photocrosslinked to an RNA with the target sequence 5'...GUA UAC GCU CUU UCA CUA using the photocrosslinking techniques described above. This RNA-linker construct (with and without prior treatment with RNase H) was then successfully used for the synthesis of RNA-protein fusions.

[0073] One advantage of the photochemical methods for attaching a peptide acceptor to an RNA is that these methods do not require chemical modification of the RNA prior to ligation. This makes the process very robust and selective, and allows the use of an RNA from a crude T7 transcription reaction as the substrate for the chemical ligation.

Example 4: Photocleavable Biotin-based RNA Purification and Ligation

[0074] If desired, an affinity-based RNA purification step may be combined with a photochemical ligation procedure described above (Figure 7H). A suitable linker molecule is modified at its puromycin terminus with a photocleavable biotin moiety (e.g., EZ-Link™ NHS-PC-LC-Biotin, Pierce, Rockford, IL). The target RNA (obtained, for example, from a crude transcription reaction) is then hybridized to a defined amount of linker, and the resulting duplex is captured on a solid support, such as streptavidin (or a related) resin. The excess RNA, as well as the components of the transcription reaction are then removed by extensive washing. Irradiation with long-wave UV light simultaneously leads to photocrosslink formation and product release from the resin. The ligated RNA can then be directly fed into a translation and fusion formation reaction, without further purification.

[0075] This method is advantageous over previous RNA purification schemes. For example, after transcription, the amount of RNA merely has to be estimated to exceed the amount of linker used. When subjected to the described procedure, its amount is automatically reduced to a quantity not more than the amount of linker used. This, in turn, allows one to proceed to the next step without further quantization of the RNA (or ligated RNA) by, for example, taking A₂₆₀ UV readings, and the RNA amounts do not have to be adjusted otherwise. The nucleic-acid protein fusion molecule preparation process is therefore more suitable for automation.

[0076] In one exemplary technique, this biotin-based RNA purification and ligation protocol may be carried out as follows. In this photocleavable biotin-based RNA purification and ligation procedure, the linker is first biotinylated. The linker C6-psoralen-2-OMe[U AGC GGA UGC] dA₁₈ TEG₂ dCdC-puromycin is biotinylated by combining 100 μ l of 100 μ M linker (10 nmol total), 50 μ l of 1 μ mole EZ-Link™ PC-LC-Biotin in DMSO, 20 μ l of 10x PBS, pH 7.4, and 30 μ l H₂O. The mixture is incubated at room temperature for 2 hours, and results in a quantitative yield. The mixture is then precipitated twice with ethanol, with an expected recovery of >90% of the PC-biotinylated linker, and resuspended in 200 μ l H₂O.

[0077] RNA is next transcribed using, for example, the T7 Megashortscript Kit (Ambion). Transcription is carried out using 10 pmole of a DNA template containing the sequence GCA UCC GCU AUU UAA A_n at the 3'-terminus for a 250 μ l reaction. This transcription reaction should yield approximately 2-5 nmol of crude RNA product. No purification (phenol extraction, NAP-5 column, or RNeasy column) is required prior to proceeding to the next step.

[0078] In the next step of this purification and ligation technique, the biotinylated linker (10 μ l of 50 pmol/ μ l biotinylated linker; 500 pmol total) is annealed to 62.5 to 250 μ l of the transcription mixture (containing an estimated minimum of 500 pmole of RNA) using, for example, a PCR machine (heating for 30 seconds to 80°C, then cooling to 4°C at 0.3°C/sec) with 15 μ l of 5 M NaCl (to a final concentration of 0.25 M for a 300 μ l reaction) and H₂O, to a final reaction volume of 300 μ l. The RNA of the reaction mixture is next immobilized onto 100 μ l of Neutravidin beads (Pierce, Rockford, IL) by gently rocking the reaction mixture at 4°C for 30 minutes. The beads are then washed and resuspended in 300 μ l H₂O.

[0079] The beads are next spun down and washed 3 times with 100 μ l of buffer (25 mM Tris pH 7.0 and 0.25 M NaCl). Then the beads are UV irradiated for 15 minutes at room temperature (using a hand-held UV lamp UVGL-25; a microcentrifuge tube containing the beads is put directly on the lamp) to chemically ligate the linker to the RNA and photo-release the ligated molecule from the beads. It is expected that 250 pmol of ligated RNA is photo-released. Seventy-five μ l of H₂O is added to the tubes, the tubes are vortexed for 30 seconds, and the heads are spun down. The 75 μ l supernatant, containing the ligated RNA/linker, is used for translation and formation of nucleic acid-protein fusion molecules.

[0080] The nucleic acid-protein fusion molecules are formed by combining the 75 μ l of supernatant from the previous step, and combining it with 225 μ l of the buffer components and lysate of the Rabbit Reticulocyte Lysate Kit (Ambion), and incubating the mixture for 30 minutes at 30°C. KCl and MgCl₂ are next added to final concentrations of 500 mM and 50 mM, respectively, and the reaction continues to incubate for 60 minutes at room temperature to produce the nucleic acid-protein fusion molecules.

Reference example 3: Peptide Acceptor Attachment to an RNA Through Strong Non-Covalent Bonds

[0081] As an alternative to covalent bond formation for the attachment of a peptide acceptor to an RNA molecule, methods relying solely on strong complex formation are also possible and are part of the present invention. One method involves the use of peptide nucleic acids (PNAs) for RNA recognition and binding, as shown in Figure 8A. PNAs are DNA mimics comprising a backbone composed of achiral and uncharged N-(2- aminoethyl) glycine units (Knudsen and Nielsen, Nucleic Acids Res. 24:494, 1996). PNAs have been shown to hybridize with sequence specificity and high affinity to complementary single-stranded DNA and to RNA. In particular, triple-helix-forming constructs comprising two PNA molecules binding to RNA, thereby forming a clamp, can provide an efficient means for strong binding of RNA, since such constructs can be extremely resistant to thermal denaturation and conditions used for *in vitro* translation (Figure 8A) (Hanvey Hanvey et al., Science, 258:1481, 1992).

[0082] The use of pseudoisocytosine bases further enhances stability at neutral and basic pH (Egholm et al., Nucleic Acids Res. 23:217, 1995). It has been demonstrated that such PNA-clamps remain associated with mRNA under *in vitro* translation conditions and cannot be displaced by the ribosome (Knudsen and Nielsen, Nucleic Acids Res. 24:494, 1996). This property maximizes the stability of the corresponding RNA-protein fusion constructs.

[0083] The preparation of nucleic acid linker-PNA constructs may be accomplished by solid phase synthesis starting with puromycin-CPG, as shown in Figure 8B and as described in Uhlmann et al. (Angew. Chem. Int. Ed. Engl. 35:2633, 1996). After assembly of the desired nucleic acid portion (or PEG-spacer, if so desired) using standard automated synthesis, the solid phase synthesis is continued by attaching the PNA domain with the appropriate reagents (for example, as described in Uhlmann et al. (*supra*)). Alternatively, the PNA can be pre-synthesized as a separate moiety (PE Biosystems, Foster City, CA), followed by chemical coupling to the desired linker portion.

[0084] In one particular example, a puromycin-DNA linker may be modified with a 5' terminal amino group, which can be further converted into a chemically activated ester (e.g., an NHS-ester through reaction with disuccinimidyl glutarate or related reagents; this technique is described, for example, in Cox et al. (J. Immunol. 145: 1719, 1990); and <http://www.piercenet.com/Products/linksearch.cfm>; Pierce, Rockford, IL). Subsequent reaction with the PNA moiety (having either an unprotected amino-terminus or a carboxy-terminal lysine) covalently links the domains. This process may be carried out in a homogenous solution containing the final DNA-linker product, or with the DNA bearing protecting groups and remaining attached to the solid resin.

Example 5: Optimization of Linker Length and Composition

[0085] For all of the strategies described above, it is preferable to optimize the linker construct. Factors to be considered, for example, are the potential inclusion of template/target recognition elements and the steric accessibility of attached functional groups. Particularly when template or target recognition through nucleic acid hybridization is involved, factors including the target sequence and the chemical nature of the linker are preferably optimized. For example, RNA hybridization strength and consequently ligation efficiency are known to be increased by the use of 2-OMe RNA or propyne-modified nucleobases, rather than DNA (as described, for example, in Inoue et al., *Nucleic Acids Res.* 15:6131, 1987); Kibler-Herzog et al., *Nucleic Acids Res.* 19:2979, 1991; and Wagner et al., *Science* 260:1510, 1993).

[0086] The linkers may also be optimized for their effectiveness in the RNA-protein fusion reaction. This will generally involve varying the length of the linker, but may also involve the use of different building blocks for RNA-protein joining. In one particular example, the deoxynucleotides of the linker may be replaced with PEG-spacers or 2-OMe-RNA units (both from Glen Research, Sterling, VA).

[0087] Other embodiments are within the claims.

Claims

1. A method of affixing a peptide acceptor to an RNA molecule, comprising:
 - (a) providing an RNA molecule; and
 - (b) chemically ligating said peptide acceptor to said RNA molecule to form a covalent bond.
2. The method of claim 1, wherein said peptide acceptor is joined to a psoralen moiety and said chemical ligation step comprises crosslinking said peptide acceptor, through said psoralen moiety, to said RNA molecule.
3. The method of claim 2, wherein said psoralen moiety is attached to said peptide acceptor through a linker.
4. The method of claim 3, wherein said psoralen moiety is positioned at the 5' terminus of said linker.
5. The method of claim 3, wherein said psoralen moiety is positioned at the 3' terminus of said linker.
6. The method of claim 3, wherein said psoralen moiety is positioned within said linker.
7. The method of claim 3, wherein said linker comprises a C6 alkyl chain.
8. The method of claim 3, wherein said RNA molecule contains a stop codon positioned proximal to its 3' end.
9. The method of claim 3, wherein said linker is between 25 and 40 nucleotide units in length.
10. The method of claim 2, wherein said crosslinking is achieved by UV light irradiation.
11. The method of claim 3, wherein, prior to said crosslinking, said RNA is hybridized to said linker which further comprises a photocleavable moiety, and said hybridized RNA is immobilized to a solid support through said photocleavable moiety.
12. The method of claim 11, wherein said photocleavable moiety is biotin.
13. The method of claim 1, wherein said RNA molecule is functionalized, and wherein a functional group is attached to said peptide acceptor.
14. The method of claim 13, wherein said RNA molecule is functionalized by IO₄-oxidation.
15. The method of claim 13, wherein said chemical ligation is carried out in the absence of an external template.
16. The method of claim 13, wherein said peptide acceptor is covalently bonded to a linker molecule and, prior to said chemical ligation step, said RNA molecule and said peptide acceptor are aligned using an external template, said external template hybridizing to the 3' end of said RNA molecule and to the 5' end of said linker molecule.
17. The method of claim 13, wherein said peptide acceptor is covalently bonded to a linker molecule and, prior to said chemical ligation step, said RNA molecule and said peptide acceptor are aligned by hybridization of said linker molecule to the 3' end of said RNA.
18. The method of claim 17, wherein said functional group of said peptide acceptor is located at the 5' end of said linker molecule.
19. The method of claim 17, wherein said functional group of said peptide acceptor is flanked by a region which hybridizes to said RNA molecule on one side and by said peptide acceptor on the other side.
20. The method of claim 13, wherein said peptide acceptor functional group is chosen from the group consisting of an amine, hydrazine, (thio)hydrazide, and (thio)semicarbazone.

21. The method of claim 1, wherein said chemical ligation step comprises:

- (a) attaching a functional group to said RNA molecule through reductive amination;
- (b) modifying a peptide acceptor to react with said functional group of said RNA molecule; and
- (c) contacting said peptide acceptor with said RNA molecule under conditions which allow covalent bond formation.

22. The method of claim 21, wherein said functional group is a thiol, maleimide, or amine.

23. The method of claim 1 or 22, wherein said RNA molecule comprises a translation initiation sequence and a start codon operably linked to a protein coding sequence.

24. The method of claim 1 or 22, wherein said peptide acceptor is puromycin.

25. The method of claim 1 or 22, wherein said peptide acceptor is covalently bonded to a non-nucleotide linker molecule.

26. The method of claim 3, wherein said linker comprises triethylene glycol spacers.

27. The method of claim 3, wherein said linker comprises 2'-OMe-RNA phosphoramidites.

28. The method of claim 1, 3, or 22, wherein said RNA or said linker contains an affinity purification sequence and said method further comprises purifying said RNA.

29. The method of claim 28, wherein said affinity purification sequence comprises a poly (A) sequence.

30. An RNA molecule crosslinked to a peptide acceptor through a psoralen moiety.

31. The RNA molecule of claim 30, wherein said RNA contains a stop codon positioned at its photocrosslink target site.

32. The RNA molecule of claim 30, wherein said peptide acceptor is ligated at the 3' end of said RNA molecule.

33. The RNA molecule of claim 30, wherein said RNA molecule comprises a translation initiation sequence and a start codon operably linked to a protein coding sequence.

34. The RNA molecule of claim 30, wherein said peptide acceptor is puromycin.

35. The RNA molecule of claim 30, wherein said psoralen moiety is attached to said peptide acceptor through a linker.

36. A method of generating an RNA-protein fusion, said method comprising:

- (a) providing an RNA molecule hybridized to a linker, said linker comprising a photocleavable moiety, a psoralen moiety, and a peptide acceptor;
- (b) immobilizing said RNA to a solid support under conditions in which non-immobilized RNA are substantially removed from the support;
- (c) crosslinking said peptide acceptor to said RNA, through said psoralen moiety, whereby said crosslinking simultaneously releases said crosslinked RNA from said solid support; and
- (d) translating the crosslinked RNA formed in step (c) to form an RNA fusion protein.

Patentansprüche

1. Verfahren zum Anbringen eines Peptidakzeptors an ein RNA-Molekül, umfassend:

- (a) Bereitstellen eines RNA-Moleküls; und
- (b) chemisches Ligieren des Peptidakzeptors mit dem RNA-Molekül, um eine kovalente Bindung zu bilden.

2. Verfahren nach Anspruch 1, wobei der Peptidakzeptor mit einer Psoralen-Einheit verbunden ist und der Schritt der chemischen Ligation Vernetzen des Peptidakzeptors, durch die Psoralen-Einheit, mit dem RNA-Molekül umfasst.

3. Verfahren nach Anspruch 2, wobei die Psoralen-Einheit durch einen Linker an den Peptidakzeptor angefügt ist.

4. Verfahren nach Anspruch 3, wobei die Psoralen-Einheit an dem 5'-Terminus des Linkers positioniert ist.

5. Verfahren nach Anspruch 3, wobei die Psoralen-Einheit an dem 3'-Terminus des Linkers positioniert ist.

6. Verfahren nach Anspruch 3, wobei die Psoralen-Einheit innerhalb des Linkers positioniert ist.

7. Verfahren nach Anspruch 3, wobei der Linker eine C₆-Alkylkette umfasst.

8. Verfahren nach Anspruch 3, wobei das RNA-Molekül ein Stopcodon, positioniert proximal zu seinem 3'-Ende, enthält.

9. Verfahren nach Anspruch 3, wobei der Linker eine Länge zwischen 25 und 40 Nucleotideinheiten hat.
10. Verfahren nach Anspruch 2, wobei das Vernetzen durch UV-Licht-Bestrahlung erreicht wird. 5
11. Verfahren nach Anspruch 3, wobei vor dem Vernetzen die RNA mit dem Linker hybridisiert wird, welcher weiterhin eine photochemisch abspaltbare Einheit umfasst, und die hybridisierte RNA durch die photochemisch abspaltbare Einheit auf einem festen Träger immobilisiert wird. 10
12. Verfahren nach Anspruch 11, wobei die photochemisch abspaltbare Einheit Biotin ist. 15
13. Verfahren nach Anspruch 1, wobei das RNA-Molekül funktionalisiert wird und wobei eine funktionelle Gruppe an den Peptidakzeptor angefügt wird. 20
14. Verfahren nach Anspruch 13, wobei das RNA-Molekül durch IO_4^- -Oxidation funktionalisiert wird.
15. Verfahren nach Anspruch 13, wobei die chemische Ligation in Abwesenheit eines äußeren Templates ausgeführt wird. 25
16. Verfahren nach Anspruch 13, wobei der Peptidakzeptor kovalent an ein Linkermolekül gebunden ist und, vor dem Schritt der chemischen Ligation, das RNA-Molekül und der Peptidakzeptor unter Verwendung eines äußeren Templates ausgerichtet werden, wobei das äußere Template mit dem 3'-Ende des RNA-Moleküls und mit dem 5'-Ende des Linkermoleküls hybridisiert. 30
17. Verfahren nach Anspruch 13, wobei der Peptidakzeptor kovalent an ein Linkermolekül gebunden ist und, vor dem Schritt der chemischen Ligation, das RNA-Molekül und der Peptidakzeptor durch Hybridisierung des Linkermoleküls mit dem 3'-Ende der RNA ausgerichtet werden. 35
18. Verfahren nach Anspruch 17, wobei sich die funktionelle Gruppe des Peptidakzeptors an dem 5'-Ende des Linkermoleküls befindet. 40
19. Verfahren nach Anspruch 17, wobei die funktionelle Gruppe des Peptidakzeptors von einer Region, welche mit dem RNA-Molekül hybridisiert, auf einer Seite und von dem Peptidakzeptor auf der anderen Seite flankiert ist. 45
20. Verfahren nach Anspruch 13, wobei die funktionelle Gruppe des Peptidakzeptors aus der Gruppe, bestehend aus einem Amin, Hydrazin, (Thio)hydrazid und (Thio)semicarbazon, ausgewählt ist. 50
21. Verfahren nach Anspruch 1, wobei der Schritt der chemischen Ligation umfasst:
 - (a) Anfügen einer funktionellen Gruppe an das RNA-Molekül durch reduktive Aminierung;
 - (b) Modifizieren eines Peptidakzeptors, um mit der funktionellen Gruppe des RNA-Moleküls zu reagieren; und
 - (c) Inkontaktbringen des Peptidakzeptors mit dem RNA-Molekül unter Bedingungen, welche kovalente Bindungsbildung erlauben.
22. Verfahren nach Anspruch 21, wobei die funktionelle Gruppe ein Thiol, Maleimid oder Amin ist.
23. Verfahren nach Anspruch 1 oder 22, wobei das RNA-Molekül eine Translationsinitiationssequenz und ein Startcodon, operabel verknüpft mit einer Proteincodierungssequenz, umfasst.
24. Verfahren nach Anspruch 1 oder 22, wobei der Peptidakzeptor Puromycin ist.
25. Verfahren nach Anspruch 1 oder 22, wobei der Peptidakzeptor kovalent an ein nicht-Nucleotid-Linker-Molekül gebunden ist.
26. Verfahren nach Anspruch 3, wobei der Linker Triethylenglycol-Spacer umfasst.
27. Verfahren nach Anspruch 3, wobei der Linker 2'-OMe-RNA-Phosphoramidite umfasst.
28. Verfahren nach Anspruch 1, 3 oder 22, wobei die RNA oder der Linker eine Affinitätsreinigungssequenz enthält und das Verfahren weiterhin Reinigen der RNA umfasst.
29. Verfahren nach Anspruch 28, wobei die Affinitätsreinigungssequenz eine Poly-(A)-Sequenz umfasst.
30. RNA-Molekül, vernetzt mit einem Peptidakzeptor durch eine Psoralen-Einheit.
31. RNA-Molekül nach Anspruch 30, wobei die RNA ein Stopcodon, positioniert an ihrer Photovernetzungs-Zielstelle, enthält.
32. RNA-Molekül nach Anspruch 30, wobei der Peptidakzeptor an dem 3'-Ende des RNA-Moleküls ligiert ist.
33. RNA-Molekül nach Anspruch 30, wobei das RNA-Molekül eine Translationsinitiationssequenz und ein Startcodon, operabel verknüpft mit einer Proteincodierungssequenz, umfasst.
34. RNA-Molekül nach Anspruch 30, wobei der Pepti-

dakzeptor Puromycin ist.

35. RNA-Molekül nach Anspruch 30, wobei die Psoralen-Einheit durch einen Linker an den Peptidakzeptor angefügt ist.

36. Verfahren zum Generieren einer RNA-Proteinfusion, wobei das Verfahren umfasst:

(a) Bereitstellen eines RNA-Moleküls, hybridisiert mit einem Linker, wobei der Linker eine photochemisch abspaltbare Einheit, eine Psoralen-Einheit und einen Peptidakzeptor umfasst;

(b) Immobilisieren der RNA auf einem festen Träger unter Bedingungen, unter welchen nicht-immobilisierte RNA im Wesentlichen von dem Träger entfernt wird;

(c) Vernetzen des Peptidakzeptors mit der RNA, durch die Psoralen-Einheit, womit das Vernetzen gleichzeitig die vernetzte RNA von dem festen Träger freisetzt; und

(d) Translatieren der vernetzten RNA, gebildet in Schritt (c), um ein RNA-Fusionsprotein zu bilden.

Revendications

1. Procédé de fixation d'un accepteur peptidique à une molécule d'ARN, comprenant:

(a) fournir une molécule d'ARN; et
(b) ligaturer chimiquement ledit accepteur peptidique à ladite molécule d'ARN pour former une liaison covalente.

2. Procédé selon la revendication 1, dans lequel ledit accepteur peptidique est joint à une fraction de psoralène et ladite étape de ligature comprend réticuler ledit accepteur peptidique, par ladite fraction de psoralène, à ladite molécule d'ARN.

3. Procédé selon la revendication 2, dans lequel ladite fraction de psoralène est attachée audit accepteur peptidique par un lieur.

4. Procédé selon la revendication 3, dans lequel ladite fraction de psoralène est positionnée à la terminaison 5' dudit lieur.

5. Procédé selon la revendication 3, dans lequel ladite fraction de psoralène est positionnée à la terminaison 3' dudit lieur.

6. Procédé selon la revendication 3, dans lequel ladite fraction de psoralène est positionnée dans ledit lieur.

7. Procédé selon la revendication 3, dans lequel ledit lieur comprend une chaîne alkyle en C₆.

8. Procédé selon la revendication 3, dans lequel ladite molécule d'ARN contient un codon d'arrêt positionné proximal à son extrémité en 3'.

9. Procédé selon la revendication 3, dans lequel ledit lieur fait entre 25 et 40 unités nucléotidiques de long.

10. Procédé selon la revendication 2, dans lequel ladite réticulation est effectuée par irradiation de lumière UV.

11. Procédé selon la revendication 3, dans lequel, préalablement à ladite réticulation, ledit ARN est hybridé audit lieur qui comprend en outre une fraction photoclivable et ledit ARN hybridé est immobilisé sur un support solide par ladite fraction photoclivable.

12. Procédé selon la revendication 11, dans lequel ladite fraction photoclivable est de la biotine.

13. Procédé selon la revendication 1, dans lequel ladite molécule d'ARN est fonctionnalisée et dans lequel un groupe fonctionnel est attaché audit récepteur peptidique.

14. Procédé selon la revendication 13, dans lequel ladite molécule d'ARN est fonctionnalisée par oxydation au IO₄.

15. Procédé selon la revendication 13, dans lequel ladite ligature chimique est effectuée en l'absence d'une matrice externe.

16. Procédé selon la revendication 13, dans lequel ledit accepteur peptidique est lié d'une manière covalente à une molécule de lieur et, préalablement à ladite étape de ligature chimique, ladite molécule d'ARN et ledit accepteur peptidique sont alignés en utilisant une matrice externe, ladite matrice externe s'hybridant à l'extrémité en 3' de ladite molécule d'ARN et à l'extrémité en 5' de ladite molécule de lieur.

17. Procédé selon la revendication 13, dans lequel ledit accepteur peptidique est lié d'une manière covalente à une molécule de lieur et, préalablement à ladite étape de ligature chimique, ladite molécule d'ARN et ledit accepteur peptidique sont alignés par hybridation de ladite molécule de lieur à ladite extrémité en 3' dudit ARN.

18. Procédé selon la revendication 17, dans lequel ledit groupe fonctionnel dudit accepteur peptidique est situé à l'extrémité en 5' de ladite molécule de lieur.

19. Procédé selon la revendication 17, dans lequel ledit

groupe fonctionnel dudit accepteur peptidique est flanqué par une région qui s'hybride à ladite molécule d'ARN d'un côté et par ledit accepteur peptidique de l'autre côté.

20. Procédé selon la revendication 13, dans lequel ledit groupe fonctionnel de l'accepteur peptidique est sélectionné parmi le groupe consistant en amine, hydrazine, (thio)hydrazide et (thio)semicarbazone.

21. Procédé selon la revendication 1, dans lequel ladite étape de ligature chimique comprend:

- (a) attacher un groupe fonctionnel à ladite molécule d'ARN par une amination réductive;
- (b) modifier un accepteur peptidique pour qu'il réagisse avec ledit groupe fonctionnel de ladite molécule d'ARN; et
- (c) mettre ledit accepteur peptidique en contact avec ladite molécule d'ARN dans des conditions qui permettent la formation d'une liaison covalente.

22. Procédé selon la revendication 21, dans lequel ledit groupe fonctionnel est un thiol, un maléimide ou une amine.

23. Procédé selon la revendication 1 ou 22, dans lequel ladite molécule d'ARN comprend une séquence d'initiation de traduction et un codon initiateur lié d'une manière opérationnelle à une séquence codante pour une protéine.

24. Procédé selon la revendication 1 ou 22, dans lequel ledit accepteur peptidique est de la puromycine.

25. Procédé selon la revendication 1 ou 22, dans lequel ledit accepteur peptidique est lié d'une manière covalente à une molécule de lieur non nucléotidique.

26. Procédé selon la revendication 3, dans lequel ledit lieur comprend des bras espaceurs en diéthylène glycol.

27. Procédé selon la revendication 3, dans lequel ledit lieur comprend des 2'-OMe-ARN phosphoramidites.

28. Procédé selon la revendication 1, 3 ou 22, dans lequel ledit ARN ou ledit lieur contient une séquence de purification par affinité et ledit procédé comprend purifier ledit ARN.

29. Procédé selon la revendication 28, dans lequel ladite séquence de purification par affinité comprend une séquence poly(A).

30. Molécule d'ARN réticulée à un accepteur peptidique par une fraction de psoralène.

31. Molécule d'ARN selon la revendication 30, où ledit l'ARN contient un codon d'arrêt positionné à son site de photoréticulation cible.

5 32. Molécule d'ARN selon la revendication 30, où ledit accepteur peptidique est ligaturé à l'extrémité en 3' de ladite molécule d'ARN.

10 33. Molécule d'ARN selon la revendication 30, où ladite molécule d'ARN comprend une séquence d'initiation de traduction et un codon initiateur lié d'une manière opérationnelle à une séquence codante pour une protéine.

15 34. Molécule d'ARN selon la revendication 30, où ledit accepteur peptidique est de la puromycine.

35. Molécule d'ARN selon la revendication 30, où ladite fraction de psoralène est attachée audit accepteur peptidique par un lieur.

20 36. Procédé de production d'une fusion ARN-protéine, ledit procédé comprenant:

- (a) fournir une molécule d'ARN hybridée à un lieur, ledit lieur comprenant une fraction photoclivable, une fraction de psoralène et un accepteur peptidique;
- (b) immobiliser ledit ARN sur un support solide dans des conditions dans lesquelles l'ARN non immobilisé est sensiblement retiré du support;
- (c) réticuler ledit accepteur peptidique audit ARN, par ladite fraction de psoralène, en vertu de quoi ladite réticulation dégage simultanément ledit ARN réticulé dudit support solide; et
- (d) traduire l'ARN réticulé formé à l'étape (c) pour former une protéine à fusion d'ARN.

Ligation on a Hairpin Template with T4 DNA Ligase




FIGURE 1

Attachment of a Puromycin-Linker using Terminal Transferase





FIGURE 2

3'-Modification of RNA through Hydrazide and Semicarbazone Formation




FIGURE 3A

3'-Modification of RNA through Reductive Amination





FIGURE 3B

Strategies for Chemical Ligation



⊕ = reactive functional group (see Figures 3A & 3B)

FIGURES 4A-4D

Hydrazide Phosphoramidite Synthesis




FIGURE 5

Chemical Ligation






FIGURE 6

Photocrosslink Formation




FIGURES 7A-7C

D



E



Linker	Composition dA _x TEG _y	Approximate length (nucleotide units)
A:	x = 20, y = 4	40
B:	x = 18, y = 2	35
C:	x = 13, y = 2	30
D:	x = 8, y = 2	25
E:	x = 12, y = 0	25
F:	x = 0, y = 6	25

FIGURES 7D-7E




FIGURE 7F




FIGURE 7G

Photocleavable Biotin-based RNA Purification and Ligation Scheme




FIGURE 7H

Attachment of Linkers through (PNA)₂-RNA Triplex Formation




FIGURE 8A

Synthesis of PNA - Linker Conjugates




FIGURE 8B

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9831700 A [0003] [0018] [0042]
- WO 98155636 A [0005]
- US 247190 A, Szostak [0018] [0037] [0042]
- US 453190 A [0069]

Non-patent literature cited in the description

- **Tuniskaya et al.** *FEBS Letters*, 1999, vol. 442, 20-24 [0006]
- **Pieles.** *Nucleic Acids Research*, 1989, vol. 17 (22), 8967-77 [0007]
- **Misiura et al.** *Nucleic Acids Res.*, 1990, vol. 18 (15), 4345-54 [0008]
- **ELLMAN et al.** *Meth. Enzymol.*, 1991, vol. 202, 301 [0032]
- **Meyer.** *Methods in Molecular Biology*. Humana Press, 1994, vol. 26, 73-91 [0044]
- **Kumar et al.** *Anal. Biochem.*, 1988, vol. 169, 376 [0044]
- **Riley et al.** *DNA*, 1986, vol. 5, 333 [0044]
- **Schmitz et al.** *Anal. Biochem.*, 1991, vol. 192, 222 [0044]
- **Agrawal.** *Methods in Molecular Biology*. Humana Press, 1994, vol. 26, 93-120 [0045]
- **Proudnikov ; Mirzabekov.** *Nucleic Acids Res.*, 1996, vol. 24, 4535 [0045]
- **Gosh et al.** *Anal. Biochem.*, 1989, vol. 178, 43 [0045]
- **BAUMAN et al.** *J. Histochem. Cytochem.*, 1981, vol. 29, 227 [0045]
- **WU et al.** *Nucleic Acids Res.*, 1996, vol. 24, 3472 [0045]
- **COX et al.** *J. Immunol.*, 1990, vol. 145, 1719 [0052] [0084]
- **PIELES ; ENGLISCH.** *Nucleic Acids Res.*, 1989, vol. 17, 285 [0054]
- **GODARD et al.** *Nucleic Acids Res.*, 1994, vol. 22, 4789 [0054]
- **GALLIE et al.** *Nucleic Acids Res.*, 1988, vol. 16, 883-93 [0059]
- **KOZAK.** *Microbiol. Rev.*, 1983, vol. 47, 1-45 [0059]
- **SINDEN ; HAGERMAN.** *Biochemistry*, vol. 23, 6299-6303 [0059]
- **GAMPER et al.** *Photochem. Photobiol.*, 1984, vol. 40, 29-34 [0059]
- **HOPP et al.** *Biotechnology*, 1988, vol. 6, 1205-1210 [0059]
- **SCHMIDT et al.** *J. Mol. Biol.*, 1996, vol. 255, 753-66 [0059]
- **BEDZYK et al.** *J. Biol. Chem.*, 1990, vol. 265, 18615-20 [0059]
- **MALLENDER et al.** *J. Biol. Chem.*, 1996, vol. 271, 5338-46 [0059]
- **MILLIGAN et al.** *Nucleic Acids Res.*, 1987, vol. 15, 8783-8798 [0060]
- **INOUE et al.** *Nucleic Acids Res.*, 1987, vol. 15, 6131-6148 [0061]
- **MAJLESSI et al.** *Nucleic Acids Res.*, 1998, vol. 26, 2224-2229 [0061]
- **PIELES et al.** *Nucleic Acids Res.*, 1989, vol. 17, 8967 [0069]
- **HANVEY et al.** *Science*, 1992, vol. 258, 1481 [0081]
- **EGHOLM et al.** *Nucleic Acids Res.*, 1995, vol. 23, 217 [0082]
- **KNUDSEN ; NIELSEN.** *Nucleic Acids Res.*, 1996, vol. 24, 494 [0082]
- **UHLMANN et al.** *Angew. Chem. Int. Ed. Engl.*, 1996, vol. 35, 2633 [0083]